Latest Company Intelligence

• UPDATE: Sanofi Unlikely To Make First Payment On Genzyme Right 
  NASDAQ.com  | Jul 28,'11
  --Former Genzyme shareholders unlikely to get $1-per-right payment --CEO Viehbacher says Genzyme was overly optimistic before deal --Production slowness, plant delay cause Fabrazyme shortage to continue (Adds details and company comments beginning the fourth paragraph.) NEW YORK -(Dow Jones)- Sanofi ( SNY , SAN .FR) said it is unlikely that its newly acquired Genzyme unit will hit key
• Evercore Posts Profit of $2.3 Million 
  DealBook - The New York Times  | Jul 28,'11
  Chip East/Bloomberg NewsRoger Altman, co-founder of Evercore Partners. Evercore Partners is still playing in the big leagues. The investment firm reported second-quarter revenue of $142 million, a 119 percent increase from the period a year earlier, and it posted a profit of $2.3 million, up from $117,000. The 43-cent-a-share profit was slightly below the 44 cents a share
• Sanofi Net Profit Falls On Patent Hits, Sales Helped By Genzyme 
  Global Finance Magazine  | Jul 28,'11
  Sanofi SA (SAN. FR) Thursday reported a 40.9% drop in second-quarter net profit as generic competition, drug price cuts in Europe and in the U.S. and currency fluctuations hit earnings, but France's largest pharmaceuticals company said sales were helped by the recent acquisition of U.S. biotech Genzyme.
• Sanofi ups EPS, expects Genzyme to miss production CVR 
  Reuters UK  | Jul 27,'11
  French drugmaker Sanofi raised its earnings forecast for 2011 now that Genzyme is part of its business, but said the U.S. biotech would likely miss its first milestone fee due to supply constraints of one of its key drugs.
• 2011 Review of Sanofi Aventis (High Yield Portfolio) 
  InvestorsInsight  | Jul 26,'11
  Sanofi-Aventis is the world's fourth largest pharmaceutical company and the largest in Europe. Its product line centers on diabetes, cardiovascular, thrombosis, metabolic disorders, cancer, central nervous system drugs (Lantus, Plavix, Lovenox Multaq and Taxotere) and vaccines. In its current corporate form, the company has almost doubled profits and its dividend in the last eight
• Beware Drug Companies that Pretend to Be Your Social Media Friend 
  Patient Safety Blog  | Jul 25,'11
  Technology is a wonderful thing. Most of us rely on it to do our jobs, remain informed, communicate and plan and participate in recreational activities. But like a wonder drug that can render a dread disease a manageable irritant, technology has side effects and some of them are dark, indeed. Writing on his health news blog, Gary Schwitzer recounts the ominous tale of a

• To See More On FirstRain, Request A Trial >